Experimental drug for rosacea meets late-stage goals

Nov. 7, 2018

Foamix announced positive results this week for its new treatment for a common skin problem.

Currently called FMX103, the experimental treatment includes a common antibiotic, minocycline, and was more successful at improving symptoms of rosacea than a foam without the antibiotic.

Around 3 million new cases of rosacea are reported each year. There is no cure for the condition, which causes facial redness and inflammatory lesions. 

Patients are typically given oral antibiotics for rosacea along with topical treatments. Foamix hopes that its new treatment combining the two will give it a competitive edge in the market. 

Read the full Reuters report.